Article

Pembrolizumab in advanced acral lentiginous melanoma: final results of a single-centre, open-label, phase II trial in an East Asian population

2026-07-23

Abstract excerpt

<h4>Background</h4> Acral lentiginous melanoma (ALM) is the predominant melanoma subtype in East Asian populations, accounting for roughly 50–58% of cases, compared with 2–3% in populations of European ancestry. ALM is genomically and biologically distinct from sun-exposed cutaneous melanoma, and East Asian and acral patients were markedly under-represented in the pivotal anti–PD-1 registration trials. At the tim...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3abb3215-b685-5412-af67-d49f15298711
DOI: 10.64898/2026.07.22.26358641

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pembrolizumab in advanced acral lentiginous melanoma: final results of a single-centre, open-label, phase II trial in an East Asian populationDOI 10.64898/2026.07.22.26358641Read

Immunotherapy for patients with melanoma in East Asia: current evidence, future directions, and clinical implications.Semantic proximity Read

Genetic characteristics and response to systemic therapies of acral lentiginous melanoma at a tertiary care center-a retrospective review.Semantic proximity Read

[Clinical studies and accepted therapies of advanced melanoma].Semantic proximity Read

Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.Semantic proximity Read

EZH2 in Acral Lentiginous Melanoma: Molecular, Epigenetic, and Therapeutic Perspectives.Semantic proximity Read

Optimal strategy in managing advanced melanoma.Semantic proximity Read

Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic MelanomaSemantic proximity Read

ERK Hyperactivation Serves as a Unified Mechanism of Escape in Intrinsic and Acquired CDK4/6 Inhibitor Resistance in Acral Lentiginous MelanomaSemantic proximity Read

Development of a Metastatic Uveal Melanoma Prognostic risk Score (MUMPS) for use in patients receiving immune checkpoint inhibitorsSemantic proximity Read

Nivolumab for unresectable cutaneous epithelial malignancies: An open-label, single-arm, multi-centre, phase II trial (NMSC-PD1)Semantic proximity Read

Genomic characterization reveals distinct mutational landscape of acral melanoma in East Asian.Semantic proximity Read

ERK Hyperactivation Represents a Unified Mechanism of Escape in Intrinsic and Acquired CDK4/6 Inhibitor Resistance in Acral Lentiginous MelanomaSemantic proximity Read